Tag: Abivax
Abivax: start of recruitment for a trial in Crohn’s – 04/10/2024 at 09:23
(CercleFinance.com) – The biotechnology company Abivax announces that the first patient has been recruited as part of its phase 2b clinical trial ENHANCE-CD (NCT06456593), evaluating obefazimod in patients with Crohn’s…
Abivax provides update on strategy of combination treatment program in ulcerative colitis (UC). – 09/25/2024 at 10:15 p.m.
ABIVAX Press Release Abivax provides an update on the strategy of the combination treatment program in ulcerative colitis (UC) and announces early preclinical data on the combination of obefazimod and…
Abivax presents its financial results for the first half of 2024. – 09/09/2024 at 22:05
ABIVAX Press Release Abivax presents its financial results for the first half of 2024. Cash balance of EUR 222 million as of June 30, 2024; financing capacity until the fourth…
Abivax: recruited the 600th patient in the trial for UC – 06/08/2024 at 10:52
(CercleFinance.com) – Abivax announces that the 600th patient has been recruited in the ABTECT phase 3 trial at the end of July 2024. The ABTECT phase 3 trial is evaluating…
Abivax: the 600th patient has been recruited in the Abtect phase 3 trial – 06/08/2024 at 11:42
(AOF) – Abivax announced that the 600th patient was enrolled in the Abtect Phase 3 trial at the end of July 2024. Based on this milestone and the current enrollment…
Abivax: phase 3 data postponed to 2nd quarter 2025
(CercleFinance.com) – Abivax announced on Tuesday that the first results of its phase 3 trial in ulcerative colitis (UC) were now expected at the beginning of the 2nd quarter of…
Abivax: Sylvie Grégoire appointed Chairwoman of the Board of Directors, visibility until end of 2025
(AOF) – Abivax (+0.47% to 12.78 euros) announces the appointment of Sylvie Grégoire as new Chairwoman of the Board of Directors, succeeding the current CEO and interim Chairman, Marc de…
Abivax provides operational update and key clinical program update. – 07/15/2024 at 10:10 PM
ABIVAX Press Release Abivax provides operational update and key clinical program update. • The Phase 3 ABTECT trial evaluating Obefazimod in moderately to severely active ulcerative colitis (UC) is progressing…
Abivax: four abstracts to be presented on obefazimod – 05/08/2024 at 3:05 p.m.
(CercleFinance.com) – Abivax announces the presentation of four scientific abstracts on its main drug candidate, obefazimod, in moderately to severely active ulcerative colitis (UC) and in a preclinical model of…
Abivax ordinary annual and extraordinary general meeting of May 30, 2024 Availability of preparatory documents – 05/07/2024 at 10:05 p.m.
PARIS, France, May 7, 2024, 10:00 PM CEST – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic…
Abivax: 261 million in cash, visibility until the end of 2025
(AOF) – Abivax (+1.19% to 13.56 euros) is up after the announcement of its results. The biotech announces a cash position of 261 million euros at the end of 2023,…
Abivax publishes its 2023 annual results and presents a progress update on the activity. – 02/04/2024 at 08:35
ABIVAX press release Abivax publishes its 2023 annual results and presents a progress update on the activity. • Financing of 500 million euros in 2023, including a capital increase of…